Cancers in France in 2015 attributable to insufficient physical activity.


Journal

Cancer epidemiology
ISSN: 1877-783X
Titre abrégé: Cancer Epidemiol
Pays: Netherlands
ID NLM: 101508793

Informations de publication

Date de publication:
06 2019
Historique:
received: 17 12 2018
revised: 07 02 2019
accepted: 12 02 2019
pubmed: 6 5 2019
medline: 28 2 2020
entrez: 6 5 2019
Statut: ppublish

Résumé

Insufficient physical activity is a known risk factor for various co-morbidities, including cancer. Globally, its prevalence has increased markedly over the past decades. The aim of this study was to estimate the proportion and number of cancers that were attributable to insufficient physical activity in France in 2015. Population attributable fractions (PAFs) and numbers of cancer cases attributable to insufficient physical activity (<30 min daily of moderate-to-vigorous physical activity) were estimated by age, sex and cancer site. Assuming a 10-year lag-period, PAFs were calculated using physical activity prevalence from a cross-sectional French population survey and cancer-specific relative risks. About half of all French adults were found to be insufficiently physically active, with great variation by age and sex. In 2015, an estimated 2973 cancer cases diagnosed in French adults aged 30y+ were attributable to insufficient physical activity, corresponding to 0.8% of all cancer cases (0.2% in men and 1.6% in women). This comprised 3.8% of all postmenopausal breast cancers (1620 cases), 3.6% of all colon cancers (902 cases) and 6.0% of all cancers of the corpus uteri (450 cases). If at least half of the recommended physical activity level was achieved, 1095 cancer cases could have been avoided. Insufficient physical activity is associated to about 3000 cancer cases in France, a country with comparatively low but increasing prevalence of this risk factor. This result is important for setting priorities in cancer prevention programmes aiming to increase physical activity in France and Europe in general.

Identifiants

pubmed: 31054835
pii: S1877-7821(18)30678-7
doi: 10.1016/j.canep.2019.02.009
pii:
doi:

Types de publication

Historical Article Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

216-220

Informations de copyright

Copyright © 2019 International Agency for Research on Cancer. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Marina Touillaud (M)

Léon Bérard Cancer Centre, 28 rue Laennec, 69008 Lyon, France; Cancer Research Centre of Lyon, UMR Inserm 1052 CNRS 5286 Centre Léon Bérard, 69008 Lyon, France.

Melina Arnold (M)

Section of Cancer Surveillance, International Agency for Research on Cancer, 150 Cours Albert Thomas, 69008 Lyon, France.

Laure Dossus (L)

Nutrition and Metabolism Section, Biomarkers Group, International Agency for Research on Cancer, 150 Cours Albert Thomas, 69008 Lyon, France.

Heinz Freisling (H)

Nutrition and Metabolism Section, Nutritional Methodology and Biostatistics Group, International Agency for Research on Cancer, 150 Cours Albert Thomas, 69008 Lyon, France.

Freddie Bray (F)

Section of Cancer Surveillance, International Agency for Research on Cancer, 150 Cours Albert Thomas, 69008 Lyon, France.

Irène Margaritis (I)

Nutrition Risk Assessment Unit, French Agency for Food, Environmental and Occupational Health & Safety (ANSES), 14 rue Pierre et Marie Curie, 94701 Maisons-Alfort Cedex, France.

Valérie Deschamps (V)

Agence Nationale de Santé Publique, Université Paris 13, Centre de Recherche en Epidémiologie et Statistiques, COMUE Sorbonne Paris Cité, 74 rue Marcel Cachin, 93017 Bobigny cedex, France.

Isabelle Soerjomataram (I)

Section of Cancer Surveillance, International Agency for Research on Cancer, 150 Cours Albert Thomas, 69008 Lyon, France. Electronic address: soerjomatarami@iarc.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH